Plain-English translation of NCT07095517 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a medication typically used for diabetes and weight loss, can help prevent colorectal cancer in younger adults. Researchers will give some people this medication over 24 weeks and measure changes in blood, stool, urine, and tissue samples to understand how the treatment might protect against cancer. The exact way the medication prevents cancer is still unknown, but weight loss and other biological changes are likely involved.
Colorectal cancer is increasingly appearing in younger people, and doctors want new ways to prevent it. This medication has shown promise for weight loss and improving health markers, but nobody knows yet whether it can actually reduce cancer risk in younger patients or how it might work.
You likely qualify if…
You likely don't qualify if…
You would receive weekly injections of the medication for up to 24 weeks, starting with a low dose that increases every 4 weeks until reaching a target dose. You'll attend four clinic visits: before starting the medication, at week 1, at weeks 9–12, and at the end of treatment. At your first and final visits, you'll undergo a flexible sigmoidoscopy (a procedure to look inside your colon), provide blood, urine, stool, and saliva samples, and have tissue biopsies taken. The whole process takes about 6 months.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Massachusetts General Hospital
Collaborators
National Cancer Institute (NCI), Cancer Research UK
Enrollment target
~20 participants
Started
February 2026
Primary completion
March 2027
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andrew T. Chan, MD, MPH
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.